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Background. Brain defect leading to developmental delay is one of the clinical manifestations of phenylketonuria. The aim of this
study was to evaluate the association between EEG abnormality and developmental delay/behavioral disorders in phenylketonuria.
Patients and Methods. 105 phenylketonuria patients, who were diagnosed through newborn screening tests or during follow-up
evaluation,wereenrolled.Patientswhowereseizure-freeforatleastsixmonthsbeforethestudywereincluded.Thedevelopmental
score were evaluated by the ASQ questionnaire (age-stage questionnaire) and the test of child symptom inventory-4 (CSI-4),
respectively. Results. 55 patients had a history of seizure more than 6 months before the study. Seventy had abnormal EEG (cases)
and 35 had normal EEG (controls). There was no signiﬁcant diﬀerence between mean phenylalanine levels in the abnormal and
normal EEG groups at the time of diagnosis, after six months and at our evaluation. Distribution of DQ level in the abnormal
and normal EEG groups revealed a signiﬁcant diﬀerence. An abnormal EEG was associated with a higher percentage of low DQ
levels. Conclusion. Paroxysmal epileptic discharges in PKU patients are important. Treatment of these EEG abnormalities may
aﬀect developmental scores or may lead to correction of some behavioral disorders in patients.
1.Introduction
Phenylketonuria is an autosomal recessive metabolic disease
which may cause brain insult in the developing brain, con-
sequently, leading to progressive neurodevelopmental delay.
In this genetic metabolic disorder, the hepatic enzyme,
phenylalanine hydroxylase (PAH), is missing. This enzyme is
necessary to break down amino acid phenylalanine to tyro-
sine. In deﬁciency of this enzyme, phenylpyruvate (phenyl-
ketone) may be detected in the urine [1].
Phenylketonuria is classiﬁed into classic phenylketonuria
(PKU) which indicates phenylalanine (Phe) levels higher
than 1200µm o l / La n dm i l dP K Ui nw h i c hP h el e v e l sa r eb e t -
ween 600µmol/L and 1200µmol/L. In mild hyperphenylala-
ninemia, Phe level is higher than normal limits, but below
600µmol [1, 2].
In early infants with phenylketonuria, the serum pheny-
lalanine level is in normal limits at birth, but begins to rise
within the ﬁrst few hours of life. Excessive phenylalanine is
generally believed to be responsible for the brain insult lead-
ing to progressive mental retardation and seizure disorder.
Without treatment, cognitive delay becomes evident within
6 months of age and is progressive [1, 2].
Although the principal biochemical defect is obvious in
inborn errors of metabolism such as PKU and other similar
disorders, the exact neurodysfunction defect is not clearly
deﬁnite [1–3].
Hyperphenylalaninemia may be simply detected in the
newborn screening test. Clinical manifestations in untreated
infants with PKU include growth failure, microcephaly, sei-
zures, dermatitis, and intellectual defect.
Remarkable clinical ﬁndings are light colored skin, hair
and eyes, eczematous rash and behavioral disorders [1–4].
Diﬀerent studies reported 25% generalized or partial sei-
zures in phenylketonuria. Infantile spasms and myoclonic
seizures are highly reported [4].2 ISRN Pediatrics
Electroencephalogram (EEG) is a noninvasive method
forcerebralinvestigation.Itisusefulforearlydetectionofab-
normalparoxysmaldischargeinthebrain.LongEEGrecord-
ing can detect abnormal epileptic discharge with or without
clinical seizure or convulsion.
EEG background activity is categorized into normal and
abnormal background activity which is classiﬁed into type 1
and type 2 of continuous and hyperactive rapid tracing and
inhighlyabnormalbackgroundactivity,inactive,paroxysmal
and low voltage plus theta activity.
In this study, we evaluated the association between EEG
abnormality and developmental delay as well as behavioral
disorders in patients diagnosed as phenylketonuria.
2. MaterialsandMethods
In this case-control study, 105 PKU patients (50 male, 55
female; mean age, 8.5 ± 6.2 years) who had been referred to
the neurometabolic clinic of Moﬁd Children Hospital, Teh-
ran, Iran from 2010 to 2011 were evaluated. These patients
were diagnosed as PKU patients through newborn screening
tests or later during follow-up evaluation for neurodevelop-
mental delay at the hospital.
The diagnosis of classic PKU was made on the basis of
serum Phe level higher than 6mg/dL in untreated infants,
(We used mg/dL for measuring serum phe level.) Urine
pterin analysis was done in order to exclude atypical PKU.
Before our study, the patients were matched according to
sex, age, and the serum phenylalanine level.
An intensive medical and family history was recorded for
all patients. Then all the patients were referred to the EEG
laboratory for EEG recording (after sleep deprivation for 10
to 12 hours).
Pediatric neurologists took the history of seizures and all
the patients who had recent seizures were excluded and only
patients who were seizure-free for at least six months before
the study were enrolled.
An informed written consent was obtained from parents
or legal guardians.
Based on EEG recording, the patients were divided into
two groups: the case group in which the patients had an ab-
normal EEG and the control group which consisted of those
with normal EEGs.
We evaluated the developmental score of the two groups
with the ASQ questionnaire (age and stage questionnaire).
After estimation of developmental score in cases and con-
trols, we detected the developmental quotient (DQ) of pa-
tients using the below equation:
DQ =
Developmental age
Actual age
× 100. (1)
We alsousedthe test ofchildsymptom inventory-4 (CSI-
4) for evaluation of behavioral disorders in children. This
behavior rating scale screens for DSM-IV emotional and be-
havioral disorders in children between 5 and 14 years of age.
The parents’ checklist was used. Parent checklist contains
97 items in a four-point response scale. It can be scored to
diagnostic model or symptom severity scores. Scoring is easy
and quick.
We evaluated Generalized Anxiety Disorder, Attention
Deﬁcit, Hyperactivity, Attention Deﬁcit Hyperactivity Dis-
order, Oppositional Deﬁant Disorder, Compulsive Disorder,
Obsession, and Autistic Behavioral Disorder in two groups.
We considered an EEG with normal background activity
and mild epileptic discharge as mild abnormal EEG. EEGs
with an abnormal background activity and deﬁnitely abnor-
mal by showing paroxysmal epileptic discharge were con-
sidered as moderately abnormal. Severely abnormal EEGs
were EEGs with continuous spikes and wave discharges or
the hypsarrhythmia pattern.
Finally, the data were compared between the patients
(cases and controls) and ANOVA and chi-square test were
applied for statistical analysis. A P value less than 0.05 was
considered signiﬁcant.
3. Results
We evaluated 105 patients (50 boys, 55 girls) with the diag-
nosis of PKU. The mean age of the patients was 8.5 ± 6.2
years.OfthesePKUpatients,52.3%(55patients)hadseizure
(more than 6 months before the study) and 47.7% (50 pa-
tients) were clinically seizure-free.
The case group consisted of 70 patients (66.6%) with an
abnormal EEG and the controls were 35 patients (33.4%)
with a normal EEG. In the case group, 37 patients (52.8%)
hadamildabnormalEEG,10patients(14.2%)hadmoderate
abnormal EEG and 23 patients (32.8%) had severe abnor-
mality in their EEG (as we considered in our evaluation and
mentioned before).
Inthecasegroup,Phelevelswere14mg/dL(mean,21.4±
9.1mg/dL) at diagnosis, 9mg/dL (mean, 10.3 ± 1.6mg/dL)
after 6 months of diagnosis, and 4mg/dL (mean, 7.31 ±
4.1mg/dL) at the time of our evaluation. The serum phe
levels in controls were 12mg/dL (mean, 17.3 ± 6.1mg/dL)
at diagnosis and from 6mg/dL (mean, 8.4±2.1mg/dL) after
sixmonthsoftreatmentto4mg/dL(mean,7.39±3.6mg/dL)
at the time of our study.
Therewasnosigniﬁcantdiﬀerencebetweenmeanpheny-
lalaninelevelsintheabnormalandnormalEEGgroupsatthe
time of diagnosis, after six months, and at our evaluation.
Our group was matched according to serum Phe level (P>
0.05) (Table 1).
In the case group (patients with an abnormal EEG), 47%
(33 patients out of 70 patients) had no clinical seizure. There
was no signiﬁcant diﬀerence between age in the two groups
regarding DQ levels (above and below 80) (P = 0.2) and no
signiﬁcantdiﬀerenceinDQlevelsbetweengenders(P = 0.7).
Comparison between head circumference (HC) and the
DQlevelshowedasigniﬁcantdiﬀerencebetweenHCandDQ
level in PKU patients (P = 0.04) (Table 2).
Distribution of DQ levels in the abnormal and normal
EEG groups (cases and controls) revealed a signiﬁcant diﬀer-
ence; an abnormal EEG was associated with a higher percen-
tage of low DQ levels (90% versus 57.1%) (P = 0.001)
(Table 3).
Patients in the case group (abnormal EEG) according to
severity of abnormality in EEG were categorized into threeISRN Pediatrics 3
Table 1: Mean Phe level in case and control groups at the time of
diagnosis, after six months and at our evaluation.
EEG Findings
Mean of Phe level (mg/dL) ± SD
At diagnosis
After 6
months of
diagnosis
At our
evaluation
Normal 17.3 ±6.18 .4 ±2.17 .39 ±3.6
Abnormal 21.4 ±9.11 0 .3 ±1.67 .31 ±4.1
P value P>0.05 (NS) P>0.05 (NS) P>0.05 (NS)
Phe = phenylalanine
NS = Non signiﬁcant.
Table 2:Associationbetweenthemeanheadcircumferenceandthe
level of DQ at birth and the time of our evaluation.
DQ level Mean of HC (cm) ± SD
At birth At our
evaluation
<90 34.3 ±1.24 9 .2 ±4.4
≥90 34.7 ±1.54 8 .3 ±6.4
P value P>0.05 (NS) P>0.05 (NS)
DQ: Developmental Quotient
NS: Nonsigniﬁcant.
Table 3: Distribution of DQ level in cases and controls.
EEG Findings DQ < 90 DQ > 90 Total P value
N (%) N (%)
(Controls) normal
EEG 20 (57.1%) 15 (42.9%) 35 P = 0.003
(Cases) abnormal
EEG 62 (88.5%) 8 (11.4%) 75
classes. Distribution of high and low DQ levels in these
three subgroups showed a signiﬁcant diﬀerence (P = 0.001)
(Table 4). In other words, a severe abnormal EEG was asso-
ciated with a higher percentage of low DQ levels.
In the behavioral-emotional scale evaluation, the fre-
quency of attention deﬁcit was 85.7% in the case group and
40% in the controls. Hyperactivity was detected in 71.4%
and 28.5% of the cases and controls, respectively. 85.7% of
the cases showed attention deﬁcit hyperactivity disorders in
comparison with 40% in the controls. Oppositional deﬁant
disorders were reported 84.2% in the case group and 34.2%
in the controls.
Generalized anxiety was observed in 74.2% and 42.8%
in cases and controls, respectively. Autistic behavior was de-
tected in 57.1% of the cases and 28.5% of the controls.
Totally, the frequency of behavioral disorder was 85.7%
incasesand42.8%incontrolpatients.Therewasasigniﬁcant
relationship between behavioral disorder and EEG abnor-
mality in our study (P<0.001) (Table 5).
4. Discussion
In neurometabolic diseases, neurodevelopmental delay, sei-
zures and behavioral disturbances are the prominent
Table 4: Distribution of DQ level based on type of EEG abnormal-
ity.
Type of
abnormal EEG
DQ < 90 DQ > 90 Total
N (%) N (%)
Mild 32 (45.7%) 5 (7.14%) 37 (52.8%)
Moderate 9 (12.8%) 1 (1.42%) 10 (14.3%)
Severe 21 (30%) 2 (2.86%) 23 (32.9%)
Total 62 (88.6%) 8 (11.4%) 70 (100%)
presentations. According to our knowledge, diﬀerent previ-
ous studies revealed the relationship between Phe level and
EEG abnormality and also between Phe level and develop-
mental delay, butthere are limited studies about the relation-
ship between EEG abnormality and developmental delay in
PKU patients.
Donker et al. studied the eﬀects of treatment of phenyla-
lanine level (special diet) on the EEG of six PKU patients.
Computerized EEG analysis showed activity appearance in
the low frequency band (2–5 cycle/second), dominant rhy-
thmfrequencychangesandsynchronousdegreechangesbet-
ween previous identiﬁed frequencies. This study described
the association between phenylalanine level and EEG chang-
es,whenPhelevelincreased,theEEGchangesintensiﬁedand
in contrast when the Phe level decreased the EEG changes
reversed, indicating that Phe or its metabolites lead to EEG
abnormalities [5].
In our study, the case group consisted of 70 patients
(66.6%) with abnormal EEGs. In our evaluation, we could
not ﬁnd any correlations between Phe level and EEG chan-
gesbecausewematchedPhelevelinthetwogroups.Between
patients with abnormal EEGs (the cases) there was a signiﬁ-
cant relationship between EEG ﬁndings and Phe level (P<
0.001).
According to P. T. Gross et al. review, in EEG recording of
PKU patients, about 45% of the patients had an abnormal
EEG and nearly 30% had a normal EEG in the beginning
which became abnormal later [6].
G. M. H. Abdel-Salam et al. study showed 25% of the
patients had seizure, but more than 50% had an abnormal
electroencephalogram, which means some PKU patients had
an abnormal EEG without any clinical seizure [7].
In our study, 44% (28 patients) of the patients with ab-
normal EEGs (out of 63 patients in the case group) had no
clinical seizure.
There is evidence that subclinical discharges can cause
psychocognitive impairment and behavioral disturbance.
Karimzadeh and Tabarestani reviewing study reported
negative eﬀects of this epileptic form discharge on the choice
reaction time, verbal and nonverbal communication and be-
havioral disorder [8].
Our study revealed 85.7% of the patients in the case
group and 42.8% of the children in the control group had
a pattern of behavioral disorders. These behavioral disorders
were in accordance with their EEG abnormalities and behav-
ioral disorders in phenylketonuria patients regardless of sei-
zure and Phe level.4 ISRN Pediatrics
Table 5: Distribution of behavioral disorders in cases and controls.
Groups Abnormal behavioral N (%) Normal behavioral N (%) Total P value
Normal EEG (controls) 15 (42.8%) 20 (57.1%) 35 P<0.001
Abnormal EEG (cases) 60 (85.7%) 10 (14.3%) 70
In Smith et al. study, the Rutter behavior questionnaire
was used for evaluation of common abnormal behaviors in
544 patients with phenylketonuria (8-year-old children).
Children had routine screening testing in the early months
of screening program; anxiety, hyperactivity and less respon-
sibilityweredetected.Allpatientsreceivedtreatmentbefore4
months. They described that these abnormal behaviors may
be the result of both psychologic stress and neurologic im-
pairment [9]. They did not review these children’s electroen-
cephalograms.
Rolle-Daya et al. also studied the EEG ﬁndings of 90 pa-
tients with classic PKU in one clinic. 73% of these patients
who were diagnosed and were treated early had a normal
EEG and 23% had mild abnormal background activity.
In patients diagnosed after 6 months of age, 31% had
normal EEGs, 24% had abnormal background activity, and
45% had abnormal paroxysmal discharges. They did not
assess the behavioral disorder or developmental EEG [10].
Thirty-four children with phenylketonuria with early
treatment were studied by Pietz et al. They determined the
prognostic value of age on the special diet in the ﬁrst three
months of life and IQ score and EEG were investigated [11].
Higher IQ scores were detected in patients with strict
dietary control in comparison with lose control. EEGs of the
154 children were recorded. Alpha-activity development was
normal while beta-activity was enhanced. Generalized slow-
ing and paroxysmal activity (with or without spikes) were
seen more frequently compared to the controls. EEG abnor-
mality was increased independent of IQ development and
EEG abnormality showed no relationship with the onset age
or the quality of dietary treatment.
In our present study, we found a signiﬁcant diﬀerence
between DQ levels in the abnormal EEG group. 74.7% of the
patients with abnormal EEG had a low DQ level; therefore,
we had a signiﬁcant relationship between abnormal EEG and
the low DQ levels (Table 3). In addition, we found a signiﬁ-
cant correlation between severity of abnormal EEGs and the
level of DQ in PKU patients (Table 4).
According to our study, (in PKU patients matched in Phe
levels), there was a signiﬁcant relationship between the ab-
normal EEGs and the low DQ level as well as the abnormal
EEGs and behavioral disorders.
5. Conclusion
Based on our ﬁndings, the prevalence of seizure was less than
EEG abnormality in PKU patients. There was a signiﬁcant
relevance between EEG abnormality and behavioral disor-
ders and developmental score in phenylketonuria regardless
of seizure or phenylalanine level.
The authors believe that physicians should pay attention
to these paroxysmal epileptic discharges in PKU patients
more than before and treatment of these EEG abnormalities
may aﬀect developmental scores or may lead to correction of
some behavioral disorders in these patients.
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